A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis.

[1]  C. Serhan,et al.  Specialized pro-resolving lipid mediators in the inflammatory response: An update. , 2010, Biochimica et biophysica acta.

[2]  B. Assael,et al.  Whole blood fatty acid analysis with micromethod in cystic fibrosis and pulmonary disease. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[3]  L. Arterburn,et al.  Docosahexaenoic Acid (DHA) and Docosapentaenoic Acid (DPAn-6) Algal Oils Reduce Inflammatory Mediators in Human Peripheral Mononuclear Cells In Vitro and Paw Edema In Vivo , 2010, Lipids.

[4]  B. Strandvik,et al.  Supplementation With Fatty Acids Influences the Airway Nitric Oxide and Inflammatory Markers in Patients With Cystic Fibrosis , 2010, Journal of pediatric gastroenterology and nutrition.

[5]  V. Lucidi,et al.  Bone and body composition analyzed by Dual-energy X-ray Absorptiometry (DXA) in clinical and nutritional evaluation of young patients with Cystic Fibrosis: a cross-sectional study. , 2009, BMC pediatrics.

[6]  M. Boaz,et al.  Association of cholesterol oxidation and abnormalities in fatty acid metabolism in cystic fibrosis. , 2009, The American journal of clinical nutrition.

[7]  D. Radzioch,et al.  Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. , 2009, American journal of respiratory cell and molecular biology.

[8]  S. Shoff,et al.  Classification of malnutrition in cystic fibrosis: implications for evaluating and benchmarking clinical practice performance. , 2008, The American journal of clinical nutrition.

[9]  H. Quinton,et al.  Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. , 2008, Journal of the American Dietetic Association.

[10]  A. Christophe,et al.  Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients. , 2008, Prostaglandins, leukotrienes, and essential fatty acids.

[11]  S. Freedman,et al.  Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[12]  J. Elborn,et al.  Clinical trials in cystic fibrosis. , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[13]  C. Serhan.  Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. , 2007, Annual review of immunology.

[14]  M. Corey,et al.  Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[15]  C. Agostoni,et al.  Dietary and Circulating Polyunsaturated Fatty Acids in Cystic Fibrosis: Are They Related to Clinical Outcomes? , 2006, Journal of pediatric gastroenterology and nutrition.

[16]  D. Mellström,et al.  Serum phospholipid fatty acid pattern is associated with bone mineral density in children, but not adults, with cystic fibrosis. , 2006, The British journal of nutrition.

[17]  T. Buclin,et al.  Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. , 2006, Clinical nutrition.

[18]  D. Ma,et al.  Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. , 2006, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[19]  C. Colombo,et al.  BMD and Body Composition in Children and Young Patients Affected by Cystic Fibrosis , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[21]  M. Regan,et al.  Association of cystic fibrosis with abnormalities in fatty acid metabolism. , 2004, The New England journal of medicine.

[22]  L. Saiman,et al.  Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. , 2003, JAMA.

[23]  Shumei S. Guo,et al.  2000 CDC Growth Charts for the United States: methods and development. , 2002, Vital and health statistics. Series 11, Data from the National Health Survey.

[24]  S. Freedman,et al.  A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Frascarolo,et al.  Essential fatty acid deficiency in well nourished young cystic fibrosis patients , 1997, European Journal of Pediatrics.

[26]  B. Strandvik,et al.  Prostanoid biosynthesis in patients with cystic fibrosis. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[27]  J. Askanazi,et al.  The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis. , 1996, Nutrition.

[28]  L. J. Baer,et al.  The absorption and effect of dietary supplementation with omega‐3 fatty acids on serum leukotriene B4, in patients with cystic fibrosis , 1994, Pediatric pulmonology.

[29]  W. Henderson,et al.  Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. , 1994, The Journal of pediatrics.

[30]  C. Sirtori,et al.  Changes of n-3 and n-6 fatty acids in plasma and circulating cells of normal subjects, after prolonged administration of 20:5 (EPA) and 22:6 (DHA) ethyl esters and prolonged washout. , 1993, Biochimica et biophysica acta.

[31]  T. Sorrell,et al.  Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4 , 1993, The Lancet.

[32]  D. Raederstorff,et al.  Influence of an increased intake of linoleic acid on the incorporation of dietary (n-3) fatty acids in phospholipids and on prostanoid synthesis in rat tissues. , 1992, Biochimica et biophysica acta.

[33]  A. R. Frisancho,et al.  New norms of upper limb fat and muscle areas for assessment of nutritional status. , 1981, The American journal of clinical nutrition.

[34]  H. Watson,et al.  Omega-3 fatty acids for cystic fibrosis. , 2013, The Cochrane database of systematic reviews.

[35]  J. Lloyd-Still,et al.  Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. , 2006, Nutrition.

[36]  B. Strandvik.  Fatty acid metabolism in cystic fibrosis. , 2004, The New England journal of medicine.

[37]  V. Raia,et al.  Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. , 2003, JPEN. Journal of parenteral and enteral nutrition.

[38]  Shumei S. Guo,et al.  CDC GROWTH CHARTS FOR THE UNITED STATES: METHODS AND DEVELOPMENT 2000 , 2002 .

[39]  F. De Baets,et al.  Increase of long chain omega-3 fatty acids in the major serum lipid classes of patients with cystic fibrosis. , 1992, Annals of nutrition & metabolism.

[40]  T. Lohman,et al.  Anthropometric Standardization Reference Manual , 1988 .